If current inhibition: cellular basis and physiology
- PMID: 16936469
- DOI: 10.1159/000095403
If current inhibition: cellular basis and physiology
Abstract
The slow diastolic depolarization phase in cardiac pacemaker cells is the electrical basis of cardiac automaticity. The hyperpolarization-activated current (I(f)) is one of the key mechanisms underlying diastolic depolarization. Particularly, I(f) is unique in being activated on membrane hyperpolarization following the repolarization phase of the action potential. I(f) has adapted biophysical properties and voltage-dependent gating to initiate pacemaker activity. I(f) possibly constitutes the first voltage-dependent trigger of the diastolic depolarization. For these reasons, I(f) is a natural pharmacological target for controlling heart rate in cardiovascular disease. In this view, I(f) inhibitors have been developed in the past, yet the only molecule to have reached the clinical development is ivabradine. At the cellular level, the remarkable success of ivabradine is to be ascribed to its relatively high affinity for f-channels. Furthermore, ivabradine is the most I(f)-specific inhibitor known to date, since moderate inhibition of other voltage-dependent ionic currents involved in automaticity can be observed only at very high concentrations of ivabradine, more than one order of magnitude from that inhibiting I(f). Finally, the mechanism of block of f-channels by ivabradine has particularly favorable properties in light of controlling heart rate under variable physiological conditions. In this article, we will discuss how I(f) inhibition by ivabradine can lead to reduction of heart rate. To this aim, we will comment on the role of I(f) in cardiac automaticity and on the mechanism of action of ivabradine on f-channels. Some aspects of the cardiac pacemaker mechanism that improve the degree of security of ivabradine will also be highlighted.
Similar articles
-
Heart rate reduction by pharmacological If current inhibition.Adv Cardiol. 2006;43:31-44. doi: 10.1159/000095404. Adv Cardiol. 2006. PMID: 16936470 Review.
-
Novel If current inhibitor ivabradine: safety considerations.Adv Cardiol. 2006;43:79-96. doi: 10.1159/000095430. Adv Cardiol. 2006. PMID: 16936474 Review.
-
Clinical perspectives of heart rate slowing for coronary event reduction and heart failure.Adv Cardiol. 2006;43:45-53. doi: 10.1159/000095405. Adv Cardiol. 2006. PMID: 16936471 Review.
-
Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents.Curr Med Res Opin. 2005 Jul;21(7):1115-22. doi: 10.1185/030079905x50543. Curr Med Res Opin. 2005. PMID: 16004681 Review.
-
Future directions: what data do we need?Adv Cardiol. 2006;43:106-111. doi: 10.1159/000095432. Adv Cardiol. 2006. PMID: 16936476 Review.
Cited by
-
Targeting the Translocator Protein (18 kDa) in Cardiac Diseases: State of the Art and Future Opportunities.J Med Chem. 2024 Jan 11;67(1):17-37. doi: 10.1021/acs.jmedchem.3c01716. Epub 2023 Dec 19. J Med Chem. 2024. PMID: 38113353 Free PMC article. Review.
-
Characterization of sinoatrial automaticity in Microcebus murinus to study the effect of aging on cardiac activity and the correlation with longevity.Sci Rep. 2023 Feb 21;13(1):3054. doi: 10.1038/s41598-023-29723-5. Sci Rep. 2023. PMID: 36810863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous